Pharma Mar, S.A. (PHMMF)

Market Cap	1.54B -5.6%
Revenue (ttm)	210.34M +7.3%
Net Income	39.90M +5,367.0%
EPS	2.29
Shares Out	n/a
PE Ratio	38.69
Forward PE	25.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,581
Open	88.72
Previous Close	88.72
Day's Range	88.72 - 88.72
52-Week Range	80.91 - 110.40
Beta	0.44
RSI	51.02
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR